Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Gross Margin (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Gross Margin over the past 3 years, most recently at 80.37% for Q4 2025.

  • Quarterly results put Gross Margin at 80.37% for Q4 2025, up 2619.0% from a year ago — trailing twelve months through Dec 2025 was 49.34% (up 2627.0% YoY), and the annual figure for FY2025 was 49.34%, up 2627.0%.
  • Gross Margin for Q4 2025 was 80.37% at Tonix Pharmaceuticals Holding, up from 58.45% in the prior quarter.
  • Over the last five years, Gross Margin for TNXP hit a ceiling of 80.37% in Q4 2025 and a floor of 63.76% in Q2 2025.
  • Median Gross Margin over the past 3 years was 42.69% (2023), compared with a mean of 29.38%.
  • Peak annual rise in Gross Margin hit 2806bps in 2025, while the deepest fall reached -1127bps in 2025.
  • Tonix Pharmaceuticals Holding's Gross Margin stood at 37.36% in 2023, then skyrocketed by 45bps to 54.18% in 2024, then surged by 48bps to 80.37% in 2025.
  • The last three reported values for Gross Margin were 80.37% (Q4 2025), 58.45% (Q3 2025), and 63.76% (Q2 2025) per Business Quant data.